Related Experiment Video
Updated: May 26, 2026

Amplitude-Integrated EEG in Infants at Risk of Hypoxic-Ischemic Encephalopathy: A Feasibility Study in Road and Air Transport in Western Australia
Published on: June 21, 2024
Australian Paediatric Surveillance Unit study of haemoglobinopathies in Australian children
Elizabeth Argent1, Phillip Emder, Paul Monagle
1Sydney Children's Hospital, Randwick, Australia. elizabeth.argent@sesiahs.health.nsw.gov.au
Insights
A study found that haemoglobinopathies, including sickle cell disease and thalassaemia, occur in Australian children. Early diagnosis and enhanced screening are recommended due to increasing population diversity.
Area of Science:
- Paediatric Haematology
- Genetic Disorders
- Public Health Surveillance
Background:
- Haemoglobinopathies are inherited blood disorders affecting red blood cells.
- Australia's diverse population presents unique challenges for identifying genetic conditions.
- Existing screening programs may not fully capture the incidence of haemoglobinopathies.
Purpose of the Study:
- To determine the incidence and types of haemoglobinopathies in Australian children.
- To analyze the distribution of haemoglobinopathies across different ethnic groups.
- To assess the timing and methods of diagnosis for these conditions in Australia.
Main Methods:
- Utilized the Australian Paediatric Surveillance Unit for case reporting (2004-2006).
- Collected data on children under 15 years with newly diagnosed haemoglobinopathies.
- Excluded carrier states like thalassaemia minor; focused on diagnosed conditions.
Main Results:
- Reported a national incidence of 0.74 per 100,000 children (<15 years).
- Confirmed 59 cases, with sickle cell disease (35.6%) and Hb H disease (28.8%) being most common.
- Identified significant gaps in parental awareness of carrier status and antenatal diagnosis rates (5.1%).
Conclusions:
- A notable number of haemoglobinopathy cases occur in Australian children, including recent immigrants.
- Current screening and testing programs require enhancement to address the evolving genetic landscape.
- Increased awareness among healthcare providers and the public is crucial for early detection.
Aim:
The aims of this study were to determine the incidence and types of haemoglobinopathies in Australian children and their distribution among ethnic groups, and to collect information on timing of diagnosis of haemoglobinopathies in Australia.
Methods:
Between January 2004 and March 2006, the Australian Paediatric Surveillance Unit asked paediatricians to report all children under 15 years of age with a newly diagnosed haemoglobinopathy. A questionnaire requesting further information was forwarded to those clinicians. Carrier states such as thalassaemia minor were excluded.
Results:
Eighty-four notifications of haemoglobinopathy were received by the Australian Paediatric Surveillance Unit, with 59 confirmed cases giving a national incidence of 0.74 per 100,000 children < 15 years of age per annum. Of 59 cases, 42 (71%) were Australian born. Twenty-nine (35.6%) children had sickle cell disease, 17 (28.8%) had Hb H disease, six (10.2%) had beta-thalassaemia major and 15 (25.4%) had compound heterozygous conditions. One child died from sickle cell disease. Of Australian born children, at least 10 mothers (23.8%) and 11 fathers (26.2%) were unaware of their carrier status pre-partum (information unavailable for 13 mothers and 17 fathers). Only 11 parents (18.6%) had risks of haemoglobinopathy discussed with them antenatally and only three cases (5.1%) were diagnosed antenatally.
Conclusions:
We found that a small but significant number of children with haemoglobinopathies are being born in Australia despite existing programmes of testing at-risk groups and neonatal screening. Haemoglobinopathies were also diagnosed in recent immigrants. Greater awareness of these conditions and enhancements of screening and detection programmes may be needed as the genetic diversity of the Australian population continues to develop.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
